Developer docs
API playgroundTry for free, no card

Search company profiles

Onkos Surgical

Full company profile

uuid0000tgz

Namestring
Onkos Surgical
Legal namestring
Onkos Surgical, Inc.
Company typeenum
Private
Founded yearint
2015
Descriptiontext

Onkos Surgical is a privately held medical device company founded in 2015 and headquartered in Parsippany, New Jersey, that develops implants, instruments, and digital planning tools for musculoskeletal oncology and complex orthopedic reconstruction. Its portfolio centers on the ELEOS Limb Salvage System, which is augmented by the BioGrip 3D-printed porous collar technology, the My3D personalized solutions platform, and the JTS Extendible Prosthesis for pediatric bone cancer patients acquired from Stryker in 2022. The company's most differentiated asset is NanoCept, a 70-nanometer antibacterial implant coating that received the first FDA De Novo authorization for an antibacterial coating on orthopedic implants in April 2024, demonstrating up to 99.999% bacterial kill rates against common operating-room pathogens.

The business generates revenue primarily through direct sales of implants and personalized surgical planning services to over 350 US academic medical institutions, supported by a field sales and clinical support team. Pricing is quote-based, determined through hospital procurement, with multi-year contract cadence and no publicly disclosed list pricing. Go-to-market is enterprise field sales augmented by a surgeon-driven adoption model that uses KOL relationships, medical conference presence (AAOS, MSTS), and high-touch case planning through the uDesign ecosystem. Distribution includes a channel partnership with Integrum AB for the OPRA osseointegration device, and a 2018 strategic agreement with 3D Systems powers the My3D virtual surgical planning platform.

Capital structure reflects a venture-backed, commercially scaling company: cumulative equity raised since 2015 exceeds $80M across multiple rounds led by 1315 Capital and Canaan Partners, supplemented by a $35M venture loan facility from Horizon Technology Finance in January 2025 to fund NanoCept commercialization. The company holds multiple FDA clearances (De Novo plus several 510(k)s), maintains a 51-100 employee headcount, and is actively investing in manufacturing capacity through a new Parsippany innovation center and a dedicated NanoCept Innovation Center in Bridgewater Township opened December 2025.

Short descriptiontext

Onkos Surgical develops implants, instruments, and personalized surgical planning solutions for musculoskeletal oncology and complex orthopedic reconstruction, serving orthopedic oncologists and complex revision surgeons at over 350 US academic medical institutions.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersParsippany, United States
HQ citystring
Parsippany
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
orthopedic implant manufacturing, musculoskeletal oncology devices, limb salvage implants, 3D printed surgical implants, personalized surgical planning
Industry3 codes
PRIMARYHLAHAEAJ
3D-Printed & Patient-Specific Implants (Custom Ortho/Spine/Cranial)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)
SECONDARYHLAHAEAA
Orthopedic Joint Reconstruction Implants (Hip/Knee/Shoulder/Elbow/Ankle)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)
SECONDARYIMAAADAG
Medical & Dental 3D Printing Services (patient-specific devices, dental labs)
Industrials, Manufacturing & Construction/3D Printing/3D Printing Services (On-Demand Manufacturing & Service Bureaus)
NAICS code3 codes
  • Surgical Appliance and Supplies Manufacturing339113
  • Surgical and Medical Instrument Manufacturing339112
  • Medical Equipment and Supplies Manufacturing3391
SIC code2 codes
  • Orthopedic, Prosthetic & Surgical Appliances & Supplies3842
  • Surgical & Medical Instruments & Apparatus3841
Product category
Orthopedic Oncology Implants
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Medical Device Sales - Implants
TypeHardware Sales
Description

Onkos Surgical generates revenue primarily through the sale of orthopedic implants and surgical devices for limb salvage, tumor reconstruction, and complex revision procedures. Products include the ELEOS Limb Salvage System, BioGrip implants, NanoCept-coated implants, My3D personalized pelvic reconstruction implants, and JTS extendible prostheses. Revenue is generated through direct hospital purchasing relationships with academic medical institutions.

onkossurgical.com
2Personalized Solutions Services
TypeProfessional Services
Description

Revenue from patient-specific 3D planning services, personalized implant design, and surgical planning collaboration. The My3D platform provides revenue through dedicated Patient Solutions Engineers facilitating surgical planning, implant design services, and coordination. Includes preoperative planning, 3D modeling, implant customization, and workflow optimization services.

onkossurgical.com
3JTS Pediatric Prosthesis
TypeHardware Sales
Description

Revenue from extendible prostheses designed for pediatric bone cancer patients. The JTS system provides a growing implant with significant clinical evidence that achieves lower limb length equality over time through non-invasive magnetic lengthening, eliminating need for multiple lengthening surgeries.

onkossurgical.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Supply Chain, Personnel, Technology or R&D, Operations, Marketing or Sales
Pricing details1 tier
1Custom implant pricing based on patient-specific requirements and procedure complexity
ModelOtherBilling cadenceMulti-year contract
Notes

Medical device implants for limb salvage and oncology procedures are priced through hospital procurement processes. Personalized solutions through My3D platform are custom quoted based on surgical planning complexity, implant specifications, and turnaround time requirements. The 6-week turnaround from CT scan to surgery for My3D pelvic reconstruction is a key service differentiator.

onkossurgical.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 7 records shown
1ELEOS Limb Salvage System
Description

A modular total joint system for patients with bone loss due to tumor, trauma, or revision surgery.

onkossurgical.com
+6 more records
Core offering1 text field

Onkos Surgical designs, manufactures, and sells specialized orthopedic implants and surgical instruments for musculoskeletal oncology and complex revision procedures, including the ELEOS Limb Salvage System, BioGrip 3D-printed implants, NanoCept antibacterial-coated implants, and JTS pediatric extendible prostheses. The company also provides personalized surgical planning services through its My3D platform, including virtual surgical planning, patient-specific 3D-printed implants, and case support for orthopedic oncologists. Products are sold directly to academic medical institutions and hospitals for limb salvage procedures in bone cancer and complex reconstruction patients.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • 99.999% bacterial kill rate (5-log reduction) in standardized in-vitro testing against bacteria commonly found in operating rooms
+5 more records
Product overview1 text field

Onkos Surgical offers a unified platform-plus-modules architecture for Precision Orthopaedics focused on musculoskeletal oncology and complex orthopaedic reconstruction. The core ELEOS Limb Salvage System serves as the primary implant portfolio, which integrates with BioGrip 3D Printed Technology for enhanced osseointegration and soft tissue attachment. The NanoCept Antibacterial Implant Technology represents a differentiated platform technology that can be applied across implant components to address intraoperative bacterial contamination. The My3D Personalized Solutions platform provides digital surgical planning and patient-specific 3D printed implants and instrumentation. The JTS Extendible Prosthesis addresses pediatric limb reconstruction needs. Supporting these are uDesign surgical planning tools and MyTray workflow solutions. Over 350 leading academic medical institutions in the US utilize Onkos solutions for complex revision and tumor orthopaedic cases.

Product and service6 records
1ELEOS Limb Salvage System
CategoryOrthopedic Implants
Description

Comprehensive end-to-end limb salvage solution featuring modular components for distal femur, proximal femur, proximal tibia, and total femoral replacement. Designed to address key clinical challenges including soft tissue failures and aseptic loosening through streamlined solutions that reduce operative complexity.

2NanoCept Antibacterial Implant Technology
CategoryOrthopedic Implant Surface Technology
Description

First FDA-granted antibacterial coating technology for orthopaedic implants. Proprietary 70-nanometer-thick coating based on quaternary ammonium molecules that kills bacteria upon contact without eluting, demonstrating up to 99.999% kill rate against bacteria commonly found in operating room environment.

3My3D Personalized Solutions
CategoryPersonalized Surgical Planning Platform
Description

Digital, patient-matched platform supporting fully personalized repair for complex long-bone and pelvis reconstruction. Includes virtual surgical planning, 3D visualization, 3D printed patient-specific implants and instrumentation, graft-matching services, and comprehensive operative support.

4JTS Extendible Prosthesis
CategoryPediatric Orthopedic Implants
Description

Patient-specific, extendible prosthesis for pediatric patients with bone cancer that achieves lower limb length equality over time through non-invasive magnetic lengthening in an outpatient setting. Leading FDA 510(k) cleared device for noninvasive lengthening of pediatric limbs with over 1,700 devices implanted worldwide since 2002.

5ELEOS with BioGrip 3D Printed Technology
Category3D Printed Orthopedic Implants
Description

Limb salvage implant featuring novel 3D-printed BioGrip porous structure designed to support bone and soft tissue ingrowth. Includes modular BioGrip collars with nano HA treatment and anatomically aligned suture holes for directional soft tissue attachment.

6My3D Personalized Pelvic Reconstruction
CategoryPatient-Specific 3D Printed Pelvic Reconstruction
Description

First-of-its-kind 3D-printed and patient-specific system for advanced pelvic reconstruction. Includes 3D printed implants, instruments, and models with advanced planning service for treatment of deformity, trauma, disease, and revisions.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
1Stryker Orthopedics
Strategic tierAcquisitionTypeOthersAnnounced on2022-06-13
Description

Onkos Surgical entered into a definitive agreement to acquire the Juvenile Tumour System (JTS) Extendible Prosthesis from Stryker Orthopedics. This acquisition expanded Onkos' pediatric musculoskeletal oncology capabilities and added the JTS growing implant to its portfolio for children with bone cancer.

onkossurgical.com
Strategic tierMinorTypeChannel Partner/ Reseller/ DistributorAnnounced on2020-01-01
Description

Onkos Surgical entered a US partnership with Integrum AB to distribute the OPRA osseointegration device. This partnership expanded the company's portfolio to include improved quality of life solutions for amputee patients, complementing the limb salvage focus.

3Insight Medical Systems
Strategic tierExploratoryTypeTechnology or IntegrationAnnounced on2018-07-09
Description

Onkos Surgical and Insight Medical Systems partnered to explore applications of ARVIS (Augmented Reality Visualization and Information System) in musculoskeletal oncology. Companies conducted a pilot project to assess augmented reality technology for surgical planning and procedure support.

onkossurgical.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2018-03-06
Description

Onkos Surgical signed a 4-year agreement with 3D Systems (NYSE: DDD) to advance personalized surgical solutions. The agreement provides Onkos priority access to 3D Systems' VSP (Virtual Surgical Planning) Orthopaedics platform. This partnership powers the My3D Personalized Solutions platform launched in 2019 for joint-sparing tumor surgery.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Market position
Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Onkos Surgical

Orthopedic Oncology Implantsonkossurgical.com

Onkos Surgical develops implants, instruments, and personalized surgical planning solutions for musculoskeletal oncology and complex orthopedic reconstruction, serving orthopedic oncologists and complex revision surgeons at over 350 US academic medical institutions.

What Onkos Surgical does

Onkos Surgical is a privately held medical device company founded in 2015 and headquartered in Parsippany, New Jersey, that develops implants, instruments, and digital planning tools for musculoskeletal oncology and complex orthopedic reconstruction. Its portfolio centers on the ELEOS Limb Salvage System, which is augmented by the BioGrip 3D-printed porous collar technology, the My3D personalized solutions platform, and the JTS Extendible Prosthesis for pediatric bone cancer patients acquired from Stryker in 2022. The company's most differentiated asset is NanoCept, a 70-nanometer antibacterial implant coating that received the first FDA De Novo authorization for an antibacterial coating on orthopedic implants in April 2024, demonstrating up to 99.999% bacterial kill rates against common operating-room pathogens.

The business generates revenue primarily through direct sales of implants and personalized surgical planning services to over 350 US academic medical institutions, supported by a field sales and clinical support team. Pricing is quote-based, determined through hospital procurement, with multi-year contract cadence and no publicly disclosed list pricing. Go-to-market is enterprise field sales augmented by a surgeon-driven adoption model that uses KOL relationships, medical conference presence (AAOS, MSTS), and high-touch case planning through the uDesign ecosystem. Distribution includes a channel partnership with Integrum AB for the OPRA osseointegration device, and a 2018 strategic agreement with 3D Systems powers the My3D virtual surgical planning platform.

Capital structure reflects a venture-backed, commercially scaling company: cumulative equity raised since 2015 exceeds $80M across multiple rounds led by 1315 Capital and Canaan Partners, supplemented by a $35M venture loan facility from Horizon Technology Finance in January 2025 to fund NanoCept commercialization. The company holds multiple FDA clearances (De Novo plus several 510(k)s), maintains a 51-100 employee headcount, and is actively investing in manufacturing capacity through a new Parsippany innovation center and a dedicated NanoCept Innovation Center in Bridgewater Township opened December 2025.

Onkos Surgical firmographics

Firmographics
Name
Onkos Surgical
Legal name
Onkos Surgical, Inc.
Website
https://onkossurgical.com
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
101–250 employees
Short description
Onkos Surgical develops implants, instruments, and personalized surgical planning solutions for musculoskeletal oncology and complex orthopedic reconstruction, serving orthopedic oncologists and complex revision surgeons at over 350 US academic medical institutions.
Ownership category
akta.pro rank

Onkos Surgical industry classification

Industry
Product category
Orthopedic Oncology Implants
NAICS
Surgical Appliance and Supplies Manufacturing (339113), Surgical and Medical Instrument Manufacturing (339112), Medical Equipment and Supplies Manufacturing (3391)
SIC
Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842), Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAHAEAJ
3D-Printed & Patient-Specific Implants (Custom Ortho/Spine/Cranial)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)
SECONDARYHLAHAEAA
Orthopedic Joint Reconstruction Implants (Hip/Knee/Shoulder/Elbow/Ankle)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)
SECONDARYIMAAADAG
Medical & Dental 3D Printing Services (patient-specific devices, dental labs)
Industrials, Manufacturing & Construction/3D Printing/3D Printing Services (On-Demand Manufacturing & Service Bureaus)

Keywords

  • Orthopedic implant manufacturing
  • Musculoskeletal oncology devices
  • Limb salvage implants
  • 3D printed surgical implants
  • Personalized surgical planning

Where Onkos Surgical is headquartered

Location

Headquarters

HQ city
Parsippany
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Onkos Surgical business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

  1. Medical Device Sales - Implants: Onkos Surgical generates revenue primarily through the sale of orthopedic implants and surgical devices for limb salvage, tumor reconstruction, and complex revision procedures. Products include the ELEOS Limb Salvage System, BioGrip implants, NanoCept-coated implants, My3D personalized pelvic reconstruction implants, and JTS extendible prostheses. Revenue is generated through direct hospital purchasing relationships with academic medical institutions.
  2. Personalized Solutions Services: Revenue from patient-specific 3D planning services, personalized implant design, and surgical planning collaboration. The My3D platform provides revenue through dedicated Patient Solutions Engineers facilitating surgical planning, implant design services, and coordination. Includes preoperative planning, 3D modeling, implant customization, and workflow optimization services.
  3. JTS Pediatric Prosthesis: Revenue from extendible prostheses designed for pediatric bone cancer patients. The JTS system provides a growing implant with significant clinical evidence that achieves lower limb length equality over time through non-invasive magnetic lengthening, eliminating need for multiple lengthening surgeries.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractCustom implant pricing based on patient-specific requirements and procedure complexity

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

Onkos Surgical product offering

Product offering

Core offering

Onkos Surgical designs, manufactures, and sells specialized orthopedic implants and surgical instruments for musculoskeletal oncology and complex revision procedures, including the ELEOS Limb Salvage System, BioGrip 3D-printed implants, NanoCept antibacterial-coated implants, and JTS pediatric extendible prostheses. The company also provides personalized surgical planning services through its My3D platform, including virtual surgical planning, patient-specific 3D-printed implants, and case support for orthopedic oncologists. Products are sold directly to academic medical institutions and hospitals for limb salvage procedures in bone cancer and complex reconstruction patients.

Product overview

Onkos Surgical offers a unified platform-plus-modules architecture for Precision Orthopaedics focused on musculoskeletal oncology and complex orthopaedic reconstruction. The core ELEOS Limb Salvage System serves as the primary implant portfolio, which integrates with BioGrip 3D Printed Technology for enhanced osseointegration and soft tissue attachment. The NanoCept Antibacterial Implant Technology represents a differentiated platform technology that can be applied across implant components to address intraoperative bacterial contamination. The My3D Personalized Solutions platform provides digital surgical planning and patient-specific 3D printed implants and instrumentation. The JTS Extendible Prosthesis addresses pediatric limb reconstruction needs. Supporting these are uDesign surgical planning tools and MyTray workflow solutions. Over 350 leading academic medical institutions in the US utilize Onkos solutions for complex revision and tumor orthopaedic cases.

Differentiator

Problem solved

Functional benefit

Brands

  • ELEOS Limb Salvage System: A modular total joint system for patients with bone loss due to tumor, trauma, or revision surgery.
  • BioGrip
  • NanoCept
  • My3D
  • JTS Extendible Prosthesis
  • uDesign
  • GenVie

Products and services

  • ELEOS Limb Salvage System Comprehensive end-to-end limb salvage solution featuring modular components for distal femur, proximal femur, proximal tibia, and total femoral replacement. Designed to address key clinical challenges including soft tissue failures and aseptic loosening through streamlined solutions that reduce operative complexity.
  • NanoCept Antibacterial Implant Technology First FDA-granted antibacterial coating technology for orthopaedic implants. Proprietary 70-nanometer-thick coating based on quaternary ammonium molecules that kills bacteria upon contact without eluting, demonstrating up to 99.999% kill rate against bacteria commonly found in operating room environment.
  • My3D Personalized Solutions Digital, patient-matched platform supporting fully personalized repair for complex long-bone and pelvis reconstruction. Includes virtual surgical planning, 3D visualization, 3D printed patient-specific implants and instrumentation, graft-matching services, and comprehensive operative support.
  • JTS Extendible Prosthesis Patient-specific, extendible prosthesis for pediatric patients with bone cancer that achieves lower limb length equality over time through non-invasive magnetic lengthening in an outpatient setting. Leading FDA 510(k) cleared device for noninvasive lengthening of pediatric limbs with over 1,700 devices implanted worldwide since 2002.
  • ELEOS with BioGrip 3D Printed Technology Limb salvage implant featuring novel 3D-printed BioGrip porous structure designed to support bone and soft tissue ingrowth. Includes modular BioGrip collars with nano HA treatment and anatomically aligned suture holes for directional soft tissue attachment.
  • My3D Personalized Pelvic Reconstruction First-of-its-kind 3D-printed and patient-specific system for advanced pelvic reconstruction. Includes 3D printed implants, instruments, and models with advanced planning service for treatment of deformity, trauma, disease, and revisions.

Quantifiable outcome

  • 99.999% bacterial kill rate (5-log reduction) in standardized in-vitro testing against bacteria commonly found in operating rooms
  • +5 more outcomes

Companies that use Onkos Surgical

Customer profile

Named customers4 records

Segments4 records

Ideal customer profiles2 records

Onkos Surgical technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Onkos Surgical partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered acquisition, minor, exploratory and core.

  • Stryker OrthopedicsacquisitionOthers · 13 June 2022Onkos Surgical entered into a definitive agreement to acquire the Juvenile Tumour System (JTS) Extendible Prosthesis from Stryker Orthopedics. This acquisition expanded Onkos' pediatric musculoskeletal oncology capabilities and added the JTS growing implant to its portfolio for children with bone cancer.
  • Integrum ABminorChannel Partner/ Reseller/ Distributor · 1 January 2020Onkos Surgical entered a US partnership with Integrum AB to distribute the OPRA osseointegration device. This partnership expanded the company's portfolio to include improved quality of life solutions for amputee patients, complementing the limb salvage focus.
  • Insight Medical SystemsexploratoryTechnology or Integration · 9 July 2018Onkos Surgical and Insight Medical Systems partnered to explore applications of ARVIS (Augmented Reality Visualization and Information System) in musculoskeletal oncology. Companies conducted a pilot project to assess augmented reality technology for surgical planning and procedure support.
  • 3D SystemscoreStrategic or Co-development Partner · 6 March 2018Onkos Surgical signed a 4-year agreement with 3D Systems (NYSE: DDD) to advance personalized surgical solutions. The agreement provides Onkos priority access to 3D Systems' VSP (Virtual Surgical Planning) Orthopaedics platform. This partnership powers the My3D Personalized Solutions platform launched in 2019 for joint-sparing tumor surgery.

Scale indicators10 records

Recent moves8 records

Expansion highlights6 records

Onkos Surgical competitors and assessment

Company assessment

Market position

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Onkos Surgical social profiles

Digital presence

Onkos Surgical compliance and trust

Trust signal

Compliance2 records

Onkos Surgical financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Onkos Surgical leadership team

Management profile

Number of profiles

Profiles6 records

Onkos Surgical funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Onkos Surgical M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Onkos Surgical

What does Onkos Surgical do?

Onkos Surgical designs, manufactures, and sells specialized orthopedic implants and surgical instruments for musculoskeletal oncology and complex revision procedures, including the ELEOS Limb Salvage System, BioGrip 3D-printed implants, NanoCept antibacterial-coated implants, and JTS pediatric extendible prostheses. The company also provides personalized surgical planning services through its My3D platform, including virtual surgical planning, patient-specific 3D-printed implants, and case support for orthopedic oncologists. Products are sold directly to academic medical institutions and hospitals for limb salvage procedures in bone cancer and complex reconstruction patients.

Is Onkos Surgical a public or private company?

Onkos Surgical is a private company. It is classified as venture growth investor backed and is currently operating.

When was Onkos Surgical founded?

Onkos Surgical was founded in 2015. It employs 101 to 250 people.

Where is Onkos Surgical based?

Onkos Surgical is headquartered in Parsippany, United States, in the North America region.

How does Onkos Surgical make money?

Three revenue lines are on record. Medical Device Sales - Implants are the primary driver. The others are personalized Solutions Services and JTS Pediatric Prosthesis.

Does Onkos Surgical have an API?

No public API is recorded for Onkos Surgical.

What industry is Onkos Surgical in?

Onkos Surgical's product category is Orthopedic Oncology Implants. Its primary akta.pro industry code is HLAHAEAJ, 3D-Printed & Patient-Specific Implants (Custom Ortho/Spine/Cranial), with a secondary code of HLAHAEAA, Orthopedic Joint Reconstruction Implants (Hip/Knee/Shoulder/Elbow/Ankle). Its NAICS code is 339113 and its SIC code is 3842.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Medical Device NetworkFDA clears Onkos Surgical’s NanoCept technologyThe FDA cleared Onkos Surgical's NanoCept antibacterial coating for expanded titanium components in its ELEOS limb salvage system, including cemented bowed segmental stems, proximal femurs, and tibial baseplates. The coating achieved up to 99.9% bacterial reduction in preclinical tests, and this is the fourth 510(k) clearance for the technology.PR NewswireOnkos Surgical® expands access to NanoCept® Antibacterial Technology for patients requiring total femoral replacementOnkos Surgical announced the market release of the ELEOS Total Femoral Adapter with NanoCept Antibacterial Technology, expanding access for total femoral replacement. Since December 2024, over 500 patients have received ELEOS implants with NanoCept. The company plans to make the coating available on additional ELEOS products in coming months.3dprint3D Printing News Briefs, August 29, 2026: Prosthetics, Pelvic Implants, Capillaries, & More - 3DPrint.comA 3D printing news roundup covered America Makes and NCDMM's $5.5 million GOTHAAM winner, General Atomics Aeronautical Systems, plus Stratasys and Limbitless Solutions' expanded prosthetics partnership, Nebraska's $8 million NSF-backed NE3D healthcare center, Onkos Surgical's 1,000th My3D pelvic implant case, and Notre Dame researchers' hybrid bioprinting of capillary networks.3D ADEPT MEDIAOnkos Surgical milestone highlights expanding use of 3D‑printed, patient‑specific pelvic implants and virtual surgical planningOnkos Surgical has delivered its 1,000th personalized My3D® patient-specific pelvic implant, marking a significant milestone in the adoption of 3D-printed orthopedic reconstruction technologies. The company utilizes this platform to provide customized implant designs and surgical planning solutions for complex cases involving bone loss or tumor involvement. This achievement underscores the growing clinical reliance on digital planning and individualized approaches in acetabular revision surgery.3D Printing IndustryOnkos Surgical’s 3D printed My3D pelvic platform crosses 1,000 surgical casesOnkos Surgical has completed its 1,000th surgical case using the My3D personalized pelvic implant platform, which utilizes 3D printing to create patient-specific implants for complex reconstructions. The company cites this milestone as evidence of successful adoption and claims that its bundled service offers competitive delivery times and pricing compared to traditional off-the-shelf alternatives. This achievement highlights the growing viability of productized, custom medical devices in addressing anatomical challenges that standard implants cannot resolve.VoxelMattersOnkos Surgical reaches 1,000th patient-specific My3D pelvic implant case | VoxelMatters - The heart of additive manufacturingOnkos Surgical has completed its 1,000th case using its My3D patient-specific pelvic implant platform, a system cleared by the U.S. Food and Drug Administration for complex pelvic reconstruction. The company reports that more than 350 academic medical institutions in the United States currently utilize this technology for cases involving bone loss or tumor involvement.TCT MagazineOnkos Surgical celebrates 1,000th patient-specific pelvic implant caseOnkos Surgical announced the completion of its 1,000th patient-specific pelvic implant case using its My3D platform. The company states that this milestone highlights the effectiveness of its 3D printing technology and personalized orthopaedic approach in addressing complex anatomical challenges. The achievement underscores the growing adoption of digital planning and custom implants among surgeons for acetabular reconstruction.PR NewswireOnkos Surgical® Announces 1,000th Personalized My3D® Patient-Specific Pelvic Implant CaseOnkos Surgical announced the completion of its 1,000th case using its My3D patient-specific pelvic implant platform. This milestone highlights the adoption of personalized 3D printing technology and virtual surgical planning for complex orthopaedic reconstructions. The company emphasizes that clinical insights from these cases continue to refine its design process.PR NewswireOnkos Surgical® Announces 500th NanoCept® Case Utilizing ELEOS™ Limb Salvage SystemOnkos Surgical announced the completion of its 500th case utilizing NanoCept Antibacterial Technology on the ELEOS Limb Salvage System since receiving De Novo authorization in 2024. The milestone case was performed in Plano, TX by Dr. Cyrus Abbaschian, marking continued adoption of the antibacterial implant coating technology in complex orthopaedic oncology and revision procedures. The company stated this reflects growing integration of NanoCept across a expanding number of institutions, with recent advancements including expanded availability across additional ELEOS components.PR NewswireOnkos Surgical® Receives FDA 510(k) Clearance for Application of NanoCept® Antibacterial Technology to Titanium Implants in the ELEOS™ Limb Salvage SystemOnkos Surgical received FDA 510(k) clearance to apply its NanoCept Antibacterial Technology to titanium implants within the ELEOS Limb Salvage System, marking the second 510(k) clearance for the technology since its original De Novo authorization and a prior clearance in October 2025 for the ELEOS Proximal Tibia. The technology is designed to reduce bacterial contamination on implants for oncology and revision patients who face elevated infection risks during complex orthopaedic procedures. The company's CEO stated this clearance enables broader integration of the antibacterial coating into implants used for limb reconstruction, though the company noted that clinical effectiveness in humans has not yet been demonstrated.